Simu K. Thomas

Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs

Theodore Darkow, Henry J. Henk, Simu K. Thomas et al. · PharmacoEconomics · 2007 · 267 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease

Bengt Winblad, Ariane K. Kawata, Kathleen Beusterien et al. · International Journal of Geriatric Psychiatry · 2007 · 100 citations

Medicine, Geriatric Medicine, Pharmacotherapy +17

Risk of Cancer Treatment—Associated Bone Loss and Fractures Among Women with Breast Cancer Receiving Aromatase Inhibitors

Betty A. Mincey, Mei Sheng Duh, Simu K. Thomas et al. · Clinical Breast Cancer · 2006 · 92 citations

Medicine, Oncology, Pharmacology +12

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients

Thomas E. Delea, Oleg Sofrygin, Simu K. Thomas et al. · PharmacoEconomics · 2007 · 81 citations

Medicine, Pharmacoeconomics, Pharmacology +17

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

Paul Mitchell, Lieven Annemans, Meghan Gallagher et al. · British Journal of Ophthalmology · 2012 · 81 citations · Full text

Medicine, Ophthalmology, Pharmacoeconomics +16